Physician profile
Erik Dingley
NPI 1255614392
$1,824.37
in general payments reported to CMS, 2019-2025
13 companies · $561 in 2025
The $561 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.61 · 2020: $119 · 2021: $159 · 2022: $269 · 2023: $416 · 2024: $238 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $507.84 | 2019-2025 | Total30, Precision7, Precision 7 |
| Abbvie INC. | $429.39 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Oyster Point Pharma, INC. | $262.75 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $166.78 | 2025 | Xdemvy |
| Allergan, INC. | $131.01 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $103.59 | 2019-2021 | |
| Dompe US, INC. | $69.06 | 2022-2025 | Oxervate |
| Abb Con-Cise Optical Group LLC | $39.19 | 2021-2023 | Contact Lens, Spectacle Lenses |
| Bausch & Lomb Americas INC. | $37.74 | 2024-2025 | Miebo, Xiidra, Infuse |
| Johnson & Johnson Vision Care, INC. | $23.24 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.99 | 2023 | |
| Coopervision INC. | $18.41 | 2025 | Myday Contact Lens |
| Aerie Pharmaceuticals, INC. | $16.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Dingley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.